top of page

Modality profile: Oncolytic Immunotherapies at #ASCO23

blonca9
Jun 3, 2023
1 min read

Updated: Jun 15, 2023

Replimune Founder and Head of R&D Robert Coffin describes the oncolytic immunotherapy approach to cancer research.

Recent Posts

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for more

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page